AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03583008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticoagulation (AC) Intervention--Academic Detailing
Description: One hour online web-based academic detailing session to develop an anticoagulant (AC) learning plan.
Study NCT03583008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticoagulation (AC) Intervention--Prescribing Practices
Description: Education and support related to anticoagulant prescribing practices.
Study NCT01932697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT01932697 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionation
Description: Undergo hyperfractionated IMRT
Study NCT01932697 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo hyperfractionated IMRT
Study NCT01932697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01932697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01474850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lung recruitment maneuver
Description: RM: peak inspiratory pressure 30 cmH2O, PEEP 15 cm H20 FiO2 0,4 (from end of surgery till extubation)
Study NCT04001088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Dosing regimen of one capsule daily for a maximum of 48 weeks.
Study NCT04001088 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing regimen of one capsule daily for a maximum of 48 weeks.
Study NCT00738647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth restorations with composite
Description: The cavity is excavated and filled according to the guidelines for composite restorations
Study NCT00738647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth restorations with composite
Description: The cavity is excavated and filled according to the guidelines for composite restorations
Study NCT00132080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steroids
Description: This study evaluates the efficacy and safety of pulse steroid therapy, when added to conventional treatment with IVIG plus aspirin, in treatment of children with acute Kawasaki disease.
Study NCT04664257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT
Description: e-CBT will be administered with weekly modules. See arm/group descriptions for more information.
Study NCT03994978 — intervention group
Intervention type: PROCEDURE
Intervention: elective sigmoidectomy
Description: elective sigmoidectomy
Study NCT02167438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hem-Avert Perianal Stabilizer
Study NCT02026765 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: traditional lens
Description: A random eyes with traditional lens
Study NCT02026765 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: heparin surface modified aspheric lens
Description: the other eye implant heparin surface modified aspheric lens
Study NCT03172728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psycho-education pamphlet
Description: psycho-education intervention, based on Cognitive Behavioral Therapy, that is easy to provide and feasible in standard perinatal care. It is intended to increase awareness of obsessive thoughts and to decrease anxiety and encourage treatment seeking.
Study NCT02314858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Personalized Video (BPV)
Description: The BPV group will view a portion of their own sleep study that took place during their overnight sleep study.
Study NCT02314858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Personalized Video (NPV)
Description: The NPV group will see a stock video of someone with OSA.
Study NCT02314858 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: The TAU group will not watch a video.
Study NCT00850369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Description: Study subjects will receive monthly transfusions with 2 units of red blood cells
Study NCT03175081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Patient undergo elective laparoscopic sleeve gastrectomy will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
Study NCT03175081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Patient undergo elective laparoscopic sleeve gastrectomy will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
Study NCT04518618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and 25 ugs fentanyl (0.5 ml)
Study NCT04518618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and fentanyl 25 ug combined with 20 ugs naloxone in 0.5 ml
Study NCT02691546 — intervention group
Intervention type: OTHER
Intervention: blood sample collection
Study NCT04448275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamics Nerve flossing
Description: Neurodynamics Nerve flossing for femoral nerve that includes two techniques inform of:~slider technique and the second is the tensioner technique
Study NCT04448275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional selected exercise program
Description: Ultrasound therapy The flexibility exercises for iliopsoas \& quadriceps The iliopsoas \& quadriceps muscles strength exercise
Study NCT04572828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical Block
Description: Two-point (at 4 and 8 o'clock only) technique will be used for paracervical block for Group 1: Waiting 1 Minute After Paracervical Block and Group 2: Waiting 3 Minute After Paracervical Block. For these groups 10 ml 2% Prilocaine (VEM İlac, Tekirdag, Turkey) will be injected for each side approximately 10 mm into the cervical stroma at the cervico-vaginal junction with a 22- gauge hypodermic needle.
Study NCT04572828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 550 mg Naproxen Sodium 60 minutes before the procedure
Description: 550 mg Naproxen Sodium (Abdi Ibrahim, Turkey) will be given to participants in the Group 4, 60 minutes before the procedure.
Study NCT04572828 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: The capped needle
Description: The capped needle model will be employed for Group 3: Control Group. After cervical and vaginal preparation with povidone iodine a capped needle will be touched the cervico-vaginal junction at 4 and 8 o'clock.
Study NCT03573596 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Description: CML patients who have failed a first stopping attempt and have used any TKI for one year will switch to dasatinib 100 mg qd for an additional 2 years before second stop attempt.
Study NCT03743766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Relatlimab (BMS-986016) - 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV.
Study NCT03743766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (BMS-936558) - 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV.
Study NCT03743766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab + Nivolumab
Description: Combination (Relatlimab + Nivolumab) therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV.
Study NCT01116752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring)
Description: In addition to glycemic control in 2 groups, all children \<1 year old and 25% of those >1 year old, will be able to receive continuous glucose monitoring via interstitial glucometry.
Study NCT04179279 — intervention group
Intervention type: DEVICE
Intervention: Gili Biosensor System (Gili Pro Biosensor)
Description: Non-contact monitoring of heart and respiratory rates using an optical device
Study NCT01870947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Study NCT01870947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuroimaging
Description: Imaging data will be acquired on a Siemens 3.0T Wide-Bore Verio MRI scanner.
Study NCT01870947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genetic and Biomarkers
Description: Patients will be asked to fast for approximately 12 hours and will have approximately 2 Tbs. of blood drawn at baseline and the end of treatment (EOT).
Study NCT04300465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 week MySlainte Program
Description: The intervention consists of a 10 week community based lifestyle intervention program. It consists of a weekly 1 hour exercise class, a weekly 1 hour health promotion workshop as well as individualised goal setting, exercise prescription and optimisation of cardioprotective medications.~This program is delivered by a multi-disciplinary team; including a physiotherapist, occupational therapist, dietitian, clinical nurse specialist and physician. It will be delivered through a registered Irish charity, Croí.
Study NCT04300465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 10 week MySlainte Program
Description: The intervention consists of a 10 week community based lifestyle intervention program. It consists of a weekly 1 hour exercise class, a weekly 1 hour health promotion workshop as well as individualised goal setting, exercise prescription and optimisation of cardioprotective medications.~This program is delivered by a multi-disciplinary team; including a physiotherapist, occupational therapist, dietitian, clinical nurse specialist and physician. It will be delivered through a registered Irish charity, Croí.
Study NCT02459457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Cisplatin
Description: patients get Paclitaxel and Cisplatin according to protocol
Study NCT02459457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Fluorouracil
Description: patients get Paclitaxel and Fluorouracil according to protocol
Study NCT02459457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Carboplatin
Description: patients get Paclitaxel and Carboplatin according to protocol
Study NCT02459457 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 1.8Gy/d, d1-5/week, 34Fx
Study NCT03900910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastric cancer prevention
Description: Participants will receive the 13C-urea breath test and those with test positive will further receive H. pylori eradication treatment.
Study NCT03900910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Execution of the program
Description: Screening program is audited by the standardized quality indicators, including the participation rate, the positivity rate, the referral-to-treatment rate, and the eradication rate .
Study NCT04545333 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: clonoSEQ Assay
Description: minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells
Study NCT03452852 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PICO
Description: NPWT with PICO (Smith and Nephew)
Study NCT03452852 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Coban 2 lite
Description: Compression bandaging with Coban 2 lite
Study NCT03862677 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational study, no intervention
Study NCT03240653 — intervention group
Intervention type: OTHER
Intervention: Stratified response to Enzyme Therapy
Description: Observational study involves review of retrospective and prospective data of participants' medical history, pathology, imaging and health questionnaires.
Study NCT03711292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antibiotic Stewardship
Description: For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with CDC core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.
Study NCT02799394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity modification, exercises and gradual return to sport
Study NCT01998789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day).
Study NCT01998789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Tacrolimus
Description: Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels.
Study NCT01531777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
Study NCT01531777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: 750 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
Study NCT00795275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin Phosphate
Description: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made
Study NCT00842244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study NCT00842244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m\^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study NCT00842244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m\^2 on day 1.
Study NCT02469142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADM tension-free hernia reparation
Description: Use ADM as opposed to nothing to repair incarcerated inguinal hernia
Study NCT00669877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses.
Study NCT00669877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) starting after rituximab completed (odd courses).
Study NCT00669877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
Study NCT01208064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacogenomic studies
Study NCT01208064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT00669877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses)
Study NCT00669877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses)
Study NCT00669877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mcg/kg
Study NCT00669877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg intrathecal day 7 +/- 2 days (odd courses); 3 gm/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
Study NCT00669877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 after the completion of Rituximab.
Study NCT04646863 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: performed by MLS® Laser Therapy (ASA Srl, Vicenza, Italy). It is designed to synchronize between two modules. One is emitting at 905 nm, with peak optical power = 25 W; each pulse is composed of a pulse train (single pulse width = 100 ns, maximum frequency 90 kHz). The frequency of the pulse trains varied between 1 and 2000 Hz. The other one is emitting at 808 nm in a continuous mode (power 1.1 W) or pulsed mode (pulses repetition rate 1-2000 Hz).
Study NCT04646863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The exercises were applied on a floor mat to achieve a full body workout with 10 repetitions for each exercise and rest for one minute before beginning the next exercise to avoid muscle fatigue as the following.~1. Modified Hundred~2. Modified Single Leg Stretch~3. One Leg Circle~4. Modified Scissors
Study NCT04646863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination
Description: laser therapy + Pilates exercises
Study NCT03259477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: precise segmental renal arterial clamping
Description: Precise segmental renal artery clamping eliminates global renal ischemia by performing highly selective clamping of single or multiple segmental arteries.
Study NCT03259477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic partial nephrectomy
Description: Laparoscopic partial nephrectomy (LPN) has been widely adopted as a minimally invasive nephron-sparing surgery for clinical T1 renal cell carcinoma(RCC).
Study NCT03259477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic partial nephrectomy
Description: Laparoscopic partial nephrectomy (LPN) has been widely adopted as a minimally invasive nephron-sparing surgery for clinical T1 renal cell carcinoma(RCC).
Study NCT02457377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic cerclage
Description: The vesico-uterine peritoneum is opened \& the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right \& left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right \& left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots \&
Study NCT01968993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nanOss Bioactive - posterolateral gutter
Description: Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
Study NCT04870008 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: The side of patient's scar that will receive the sutures placed at 2 or 5 mm from wound edge.
Study NCT02712268 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Checklist
Description: Introduction of a 5-point checklist to be used by all physicians on the internal medicine wards to review and adapt the medications of the patient.
Study NCT01208064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Study NCT01208064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment